Erectile Dysfunction Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. While occasional difficulty with erection is normal, ED is clinically significant when it occurs in more than 50% of sexual encounters over a minimum of 3 months. ED affects an estimated 150–200 million men worldwide, with prevalence increasing from approximately 12% in men aged 40–49 to over 60% in men aged 70 years and older, based on the landmark Massachusetts Male Aging Study. Erection is a complex neurovascular event coordinated by the central nervous system, the autonomic nervous system, penile arterial inflow, and corpus cavernosum smooth muscle relaxation. Sexual arousal activates parasympathetic fibres from the sacral spinal cord (S2–S4), releasing nitric oxide (NO) from cavernosal nerve terminals and endothelial cells. NO activates guanylyl cyclase, producing cyclic GMP (cGMP), which relaxes cavernosal smooth muscle, dilates the helicine arteries, and fills the lacunar spaces with blood — compressing subtunical venules against the tunica albuginea (the veno-occlusive mechanism), creating a rigid erection. Phosphodiesterase type 5 (PDE5) degrades cGMP, terminating the erection. This mechanism is the pharmacological target of PDE5 inhibitor drugs (sildenafil, tadalafil, vardenafil, avanafil). ED is frequently a manifestation of systemic vascular disease — the same atherosclerosis that causes coronary artery disease narrows the small cavernous arteries of the penis, and ED often predates overt cardiovascular events by 2–5 years. Guidelines recommend cardiovascular risk stratification for all men presenting with ED, as it may be the first clinical manifestation of subclinical cardiovascular disease. Psychological factors — performance anxiety, relationship distress, depression — contribute to ED in up to 40% of young men and often coexist with organic causes in older men.

ED results from vascular, neurological, hormonal, structural, or psychological causes — often in combination. Vascular (arteriogenic) ED is the most common organic cause, resulting from atherosclerosis, hypertension, dyslipidaemia, and diabetes mellitus reducing cavernosal arterial inflow. Diabetes is a particularly potent cause, affecting both small vessel endothelial function and autonomic neuropathy — approximately 35–75% of men with diabetes develop ED. Venogenic ED from cavernosal veno-occlusive dysfunction (venous leak) prevents the lacunar spaces from maintaining pressure during erection. Neurogenic ED results from neurological conditions disrupting the autonomic innervation of the penis: spinal cord injury, multiple sclerosis, Parkinson's disease, pelvic surgery (radical prostatectomy, cystectomy, abdominoperineal resection) injuring the cavernous nerves, and pelvic radiation. Post-radical prostatectomy ED affects 20–80% of men depending on nerve-sparing technique, surgeon experience, and patient age. Hormonal causes include hypogonadism (testosterone deficiency — present in 10–25% of ED patients), hyperprolactinaemia, and thyroid disorders. Structural causes include Peyronie's disease (fibrous plaques within the tunica albuginea causing penile curvature and pain during erection) and post-priapism corporal fibrosis. Medications causing ED include antihypertensives (thiazide diuretics, non-selective beta-blockers), antidepressants (SSRIs — particularly sertraline and paroxetine), antipsychotics, antiandrogens, finasteride, and chemotherapy. Lifestyle factors — smoking, obesity, excessive alcohol, sedentary behaviour, and recreational drug use — contribute independently to ED through endothelial dysfunction, testosterone suppression, and autonomic dysregulation.

All men presenting with ED should undergo a structured assessment. History includes ED duration, severity (IIEF-5 or SHIM questionnaire score — maximum 25, with 1–7 severe, 8–11 moderate, 12–16 mild-moderate, 17–21 mild, 22–25 no dysfunction), morning erections (preserved morning erections suggest psychogenic component), sexual desire (low libido suggests hypogonadism), ejaculatory function, relationship factors, and relevant medical and medication history. Physical examination includes blood pressure, waist circumference and BMI (obesity-ED association), genital examination (penile curvature, testicular size, signs of hypogonadism), and lower extremity vascular assessment. Laboratory investigations: fasting glucose, HbA1c, lipid panel, serum testosterone (total and free, collected morning, 8–11 am due to diurnal variation — repeat if borderline), luteinising hormone (LH) and prolactin if testosterone is low. Specialised investigations — penile colour duplex Doppler ultrasound (CDDU) evaluating peak systolic velocity (normal above 30 cm/s) and end-diastolic velocity (above 5 cm/s suggests venous leak) after intracavernosal pharmacological stimulation — are reserved for men considering revascularisation or implant surgery. PDE5 inhibitor therapy is contraindicated in men on nitrate medications (absolute contraindication — severe hypotension risk), those with recent stroke, unstable angina, or uncontrolled hypotension. Testosterone replacement therapy (TRT) is indicated for confirmed hypogonadism (total testosterone below 300 ng/dL or 10.4 nmol/L) with symptoms — but patients must understand TRT impairs spermatogenesis and is contraindicated in prostate cancer, untreated sleep apnoea, or haematocrit above 52%.

Treatment follows a stepwise approach from least to most invasive, incorporating patient and partner preferences. First-line: PDE5 inhibitors selectively inhibit phosphodiesterase-5, prolonging cGMP-mediated smooth muscle relaxation to enable erection with sexual stimulation. Four agents are available: sildenafil (Viagra — 25–100 mg on-demand, onset 30–60 min, duration 4–6 hours); tadalafil (Cialis — 5 mg daily for continuous therapy, or 10–20 mg on-demand, duration 36 hours, allowing more spontaneous intercourse); vardenafil (Levitra — 5–20 mg on-demand, onset 30–60 min); avanafil (Stendra — 50–200 mg on-demand, fastest onset at 15–30 min). Generic sildenafil and tadalafil are now widely available, dramatically reducing cost. PDE5 inhibitors are effective in 60–80% of general ED patients but only 40–60% of diabetic men and 50–70% of post-prostatectomy men. Low-intensity extracorporeal shockwave therapy (Li-ESWT) applied to the penile shaft using a probe (6–12 sessions, 1,500–3,000 shockwaves per session) promotes neovascularisation and endothelial regeneration, with evidence for improving erectile function in mild to moderate vasculogenic ED, especially when combined with PDE5 inhibitors. Second-line: Vacuum erection device (VED) — a cylinder placed over the penis creates negative pressure via a hand or electric pump, drawing blood into the corpora and a constriction ring at the penile base traps blood during intercourse. Effective in over 80% of men; the ring must be removed after 30 minutes. Intracavernosal injection (ICI) of alprostadil (prostaglandin E1 — 5–40 mcg), papaverine, phentolamine, or tri-mix (three-drug combination) directly into the corpora cavernosum via a fine needle, producing erection within 5–15 minutes regardless of sexual stimulation. Effective in 85–90% of cases. Intraurethral alprostadil (MUSE — Medicated Urethral Suppository for Erection) is an alternative for men unwilling to inject. Third-line (surgical): Inflatable penile prosthesis (IPP) — a three-piece hydraulic device with twin penile cylinders, a scrotal pump, and an abdominal reservoir — provides mechanical rigidity by fluid transfer on demand. Patient satisfaction exceeds 90% at 5 years. Malleable (semi-rigid) rod prosthesis is a simpler, lower-cost alternative with no fluid mechanics, appropriate for men with limited manual dexterity. Revascularisation surgery (penile arterial revascularisation using the inferior epigastric artery) is reserved for young men (under 55) with confirmed arteriogenic ED from focal pudendal artery injury.

PDE5 inhibitors restore satisfactory erections in 60–80% of men across all ED aetiologies, with the highest response rates in psychogenic ED (80–90%) and lowest in post-radical prostatectomy ED without nerve-sparing (30–40%). Daily tadalafil 5 mg improves erectile function progressively over 4–12 weeks as endothelial function improves. Lifestyle modification — weight loss of 10% body weight, regular aerobic exercise (3–4 hours per week), smoking cessation, and Mediterranean dietary pattern — alone restores erectile function in approximately 30% of men with mild to moderate vasculogenic ED (Esposito et al., JAMA 2004) and enhances the efficacy of pharmacological treatment. Testosterone replacement therapy in hypogonadal men restores erectile function, libido, energy, and mood — with erection response to TRT alone reaching 40–60%, improved to 75–80% when combined with a PDE5 inhibitor. Intracavernosal injection therapy achieves erections in 85–90% of men regardless of neurological or vascular aetiology, including in men for whom PDE5 inhibitors are contraindicated (nitrate users) or ineffective. Penile prosthesis implantation achieves patient and partner satisfaction rates of 90–95% at 5 years, the highest of any ED intervention. Infection rate with modern antibiotic-impregnated implants (InhibiZone, Titan) is below 1%. The prosthesis provides erection on demand without pills or injections, supporting sexual spontaneity and intimacy.

PDE5 inhibitors are generally well-tolerated but cause vasodilatory side effects including headache (15–20%), facial flushing (10–15%), nasal congestion, dyspepsia, and transient visual disturbances (blue-tinged vision with sildenafil due to mild PDE6 inhibition in photoreceptors). Severe hypotension occurs with co-administration of nitrates (absolute contraindication) or alpha-blockers at higher doses (timing separation recommended). Non-arteritic anterior ischaemic optic neuropathy (NAION), a rare cause of sudden visual loss, has been reported with PDE5 inhibitors in men with pre-existing vascular risk factors and optic disc crowding — the risk is very small (approximately 2 per 100,000 users) but patients with prior NAION should avoid PDE5 inhibitors. Testosterone replacement therapy suppresses the hypothalamic-pituitary-gonadal axis — causing azoospermia in 90% of men within 3 months — and is therefore contraindicated for men pursuing fertility. Other TRT risks: erythrocytosis (haematocrit monitoring mandatory), sleep apnoea worsening, acne, and a theoretical cardiovascular risk that remains debated in the literature. Intracavernosal injections cause penile pain in 10–20% of men and carry a 1–3% risk of priapism (prolonged erection exceeding 4 hours requiring immediate medical treatment to prevent permanent fibrosis). Long-term injection use is associated with corporal fibrosis and nodule formation. Vacuum devices may cause pain, petechiae, numbness, and impaired ejaculation from the constriction ring. Penile prosthesis implantation carries surgical risks including infection (below 2% with antibiotic-coated devices), mechanical malfunction requiring reoperation (5–10% at 5 years), auto-inflation, and the psychologically irreversible nature of the procedure — natural erections are permanently lost due to corporal fibrosis after explantation.

Follow-up timing depends on the treatment modality. After initiating PDE5 inhibitor therapy, a 4–6 week follow-up using the IIEF-5 questionnaire documents treatment response. If response is suboptimal, dose optimisation, instruction on timing and sexual stimulation requirements (PDE5 inhibitors require stimulation — they are not aphrodisiacs), and addressing contributing factors (poor glycaemic control, obesity, testosterone deficiency) are pursued before declaring treatment failure. Men who fail two PDE5 inhibitors at maximum dose should be considered for second-line options. After testosterone replacement therapy, serum total testosterone at 3 months confirms therapeutic levels (target 400–700 ng/dL); haematocrit monitoring at 3 and 6 months then annually (withhold TRT if above 52%); prostate-specific antigen (PSA) monitoring in men over 40 at baseline, 3–6 months, then annually; and digital rectal examination annually. After intracavernosal injection initiation, in-clinic demonstration with dose titration is standard practice. The starting dose of alprostadil is 5–10 mcg, titrated to an erection lasting 30–60 minutes. Men are instructed to present immediately if an erection exceeds 4 hours. After penile prosthesis implantation, the device is activated at 4–6 weeks post-surgery when periprosthetic oedema resolves. Instruction in pump mechanism and cylinder cycling exercises prevents capsule formation. Annual review assesses device function and patient satisfaction.

ED treatment costs vary substantially by modality, country, and whether medications are branded or generic. PDE5 inhibitors — brand name sildenafil (Viagra): USD 15–35 per tablet in the USA; generic sildenafil: USD 0.30–2 per tablet in India, USD 1–5 in the UK. Brand tadalafil (Cialis): USD 25–70 per tablet in the USA; generic tadalafil: USD 0.50–3 in India. Low-intensity shockwave therapy (Li-ESWT): USD 300–1,200 for a course of 6–12 sessions in India; USD 2,000–5,000 in the USA. Vacuum erection device: one-time cost of USD 30–80 (manual pump) in India or USD 100–400 in the USA; a reusable investment. Intracavernosal alprostadil (Caverject): USD 10–30 per injection in India; USD 50–150 per dose in the USA. Tri-mix compounded preparations: approximately USD 100–200 per vial (20–40 doses) in the USA. Testosterone replacement therapy — injectable testosterone cypionate or enanthate: USD 5–15 per injection in India; USD 20–80 in the USA. Transdermal testosterone gel: USD 30–80 per month in India; USD 200–600 per month brand in the USA. Penile prosthesis implantation — inflatable 3-piece IPP: India USD 5,000–12,000 (device cost USD 2,000–4,000; surgeon and hospital fees); Thailand USD 8,000–18,000; Turkey USD 6,000–15,000; USA USD 18,000–45,000; UK GBP 12,000–25,000. Generic device options (AMS Spectra, Promedon Tube) available at accredited Indian centres reduce device costs by 40–60% versus AMS 700 or Coloplast Titan brand implants.

Lifestyle modification is both a standalone treatment and an evidence-based complement to pharmacological therapy. A 2014 Cochrane review confirmed that structured aerobic exercise (40 minutes, 4 times weekly for 6 months) significantly improved erectile function in men with vasculogenic ED, independently of PDE5 inhibitor use. Pelvic floor physiotherapy (Kegel exercises targeting the ischiocavernosus and bulbocavernosus muscles) was shown in a randomised trial by Dorey et al. to improve ED as effectively as sildenafil at 6 months in men with mild to moderate vasculogenic ED. Mediterranean dietary pattern (high fruit, vegetables, legumes, nuts, olive oil, fish; low red meat and refined carbohydrates) reduces ED severity by addressing endothelial dysfunction and insulin resistance. Psychosexual therapy — cognitive behavioural therapy, sensate focus exercises, couple therapy — is the primary treatment for psychogenic ED and is recommended alongside any pharmacological treatment when psychological factors contribute. Phosphodiesterase type 5 inhibitors for daily use at low dose (tadalafil 5 mg, sildenafil 25 mg) function as penile rehabilitation therapy after nerve-sparing radical prostatectomy, maintaining oxygenation of cavernosal smooth muscle and reducing fibrosis during nerve regeneration. Stem cell therapy and platelet-rich plasma (PRP) injection into the corpora cavernosa are investigational treatments with limited evidence from small trials; neither is approved for standard clinical use. Herbal supplements (yohimbine, Korean red ginseng, L-arginine, DHEA) have limited, inconsistent evidence; patients should disclose their use to their physician as they carry drug interaction risks.